

Impact Statement

The Situation

*OUR TEAM AT **BANK OF AMERICA** IS ADVISING A PRIVATE EQUITY FIRM ON A NEW ACQUISITION. THE FIRM IS LOOKING FOR A COMPANY IN THE ROBUST HEALTHCARE INDUSTRY THAT DEMONSTRATES FINANCIAL HEALTH, INNOVATION, AND OPPORTUNITIES FOR GROWTH. THEN, ONCE A BUSINESS IS ACQUIRED, OUR TEAM WILL HELP DEVELOP CREATIVE SOLUTIONS TO PROJECT THE COMPANY OVER THE COURSE OF FIVE YEARS.*

Extension Response

*THROUGH ANALYSIS, OUR TEAM FOUND **ONCOGUARD DIAGNOSTICS**, AN EMERGING BIOTECH COMPANY, TO BE A PERFECT ACQUISITION. THROUGH NON-INVASIVE AND PRECISE TESTING, **ONCOGUARD** IS REVOLUTIONIZING CANCER DETECTION. AS CANCER IS AN ONGOING HEALTH AILMENT AROUND THE WORLD, THIS BUSINESS IS MORE THAN RELEVANT FOR THE EXTENDED FUTURE. THE BUSINESS IS SCALABLE, WHICH CAN BE SEEN IN EXPANDED PARTNERSHIPS WITH HOSPITALS, EXTENDED TYPE OF CANCER RESEARCH, AND FURTHER APPLICATION OF **AI** IN THE LIQUID BIOPSY AND SCREENING PROCESS.*

The Impact

*WE BELIEVE THAT **ONCOGUARD** IS SITUATED TO EXCEL, SAVING MORE LIVES, AIDING MORE HOSPITALS IN CANCER APPROACHES, AND DRIVING PROFIT WHILE DOING SO. BEYOND THAT, AS A BIOTECH COMPANY, **ONCOGUARD** PRIORITIZES RENEWABLE RESOURCES TO EXECUTE THEIR MISSION, MAKING IT ETHICALLY SUSTAINABLE. THROUGH OUR RECOMMENDATIONS OF DIVERSIFYING PARTNERSHIPS AND INCREASING SUPPLY CHAIN EFFICIENCY, THE COMPANY CAN BE SET UP TO **IPO** AT THE END OF FIVE YEARS, PROVIDING THE **PE** FIRM WITH A CLEAR EXIT STRATEGY.*